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Evidence for mutual interdependence of epithelium and stromal lymphoid
cells in a subset of papillary carcinomas
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Summary We have correlated the morphological features of 30 human thyroid carcinomas with the cellular
localisation of insulin-like growth factor 1 (IGF-1) mRNA and IGF-1 receptor peptide using in situ hybridisa-
tion with digoxigenin-labelled oligoprobes and immunohistochemistry. Four of the five follicular carcinomas
studied showed a consistent, uniform, strong positivity for IGF-I mRNA in tumour cells compared with
weakly positive surrounding normal follicular tissue and negative stroma. The majority of papillary car-
cinomas showed weak to moderate epithelial positivity for IGF-I mRNA and negative stroma. Immunohis-
tochemistry for IGF-1 receptor showed moderate positivity confined to the tumour epithelial cells in both
follicular and the majority of papillary carcinomas. However, in a subgroup of papillary carcinomas charac-
terised by a diffuse stromal lymphoid infiltration (n = 5), the stromal cells showed a much stronger reactivity
for IGF-1 mRNA than the tumour or background thyroid, and the tumour cells showed a uniformly high
level of immunoreactivity for IGF-1 receptor. These results are compatible with the growth of the papillary
carcinoma in these cases being the result of a symbiotic relationship between the stromal lymphoid cells and
the tumour epithelium with the lymphoid cells responding to an antigen produced by the tumour cells and the
tumour cells responding to a growth factor produced by the lymphoid infiltrate. We suggest that this
mechanism may be important in other tumours. regularly associated with a widespread lymphoid
infiltrate.
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The local production of growth factors is important for the
control of normal and neoplastic cell growth. Acquisition of
autocrine secretion of growth factors combined with expres-
sion of their receptors, is thought to play a significant role in
neoplastic transformation (Daughaday, 1990). The key factor
involved in the growth of the normal human thyroid fol-
licular cell is thyroid-stimulating hormone (TSH), but it has
been shown in culture that insulin-like growth factor 1 (IGF-
1) is necessary for the growth response to TSH (Williams et
al., 1987). Autocrine production of IGF-1 has also been
suggested as one of the mechanisms involved in growth
control of human follicular adenomas (Williams et al., 1988,
1989). Many other growth factors have also been implicated
in thyroid growth, but IGF-1 and TSH are probably the
most important in normal growth. In vivo, the maintenance
of organised tissue architecture requires communication
between epithelium and stroma and their interaction may be
important for the role of IGF-1 in thyroid growth. However
the relative roles of follicular cells and stroma in the produc-
tion of IGF-1 in thyroid tumours has not been determined.
In view of its documented importance in thyroid follicular
cell growth in vitro, it is likely that IGF-1 plays an important
role in the control of coordinated growth of the thyroid in
vivo, whether in normal or neoplastic tissue.
Few previous studies have been carried out to localise
IGF-1 production in the thyroid in vivo. Interpretation of
immunocytochemistry for IGF-I peptide is complicated by
the possibility of antibody cross-reaction with the structurally
similar insulin-like growth factor 2 (IGF-2; Ollis et al., 1989).
A previous study using radioactive in situ hybridisation (ISH)
in normal breast tissue showed that IGF-I mRNA was
localised to the stroma, but in neoplasia it was localised to
the tumour cells, suggesting a switch to autocrine production
during the neoplastic process (Yee et al., 1989). However,
accurate cellular localisation has proved to be difficult using
radioactively labelled probes. We have therefore used a non-
radioactive approach which allows good cellular localisation
and ease of differentiation between stromal and epithelial
staining.
We have recently developed a sensitive technique using
digoxigenin-labelled oligonucleotide probes to demonstrate
mRNA in routine, paraffin-embedded sections from archival
material (Thomas et al., 1993; Neonakis et al., 1994).
Previous work, using oligoprobes complementary to IGF-1
mRNA in the mouse have shown that the follicular cell is the
source of IGF-1 in the growing mouse thyroid (Thomas et
al., 1994). We have now applied this technique to sections of
thyroid papillary and follicular carcinomnas to localise IGF-1
mRNA and combined this with studies of localisation of its
receptor by immunocytochemistry in serial sections to
elucidate the role of IGF-1 in the pathogenesis of these two
morphologically distinct tumours.
Material and methods
Thirty cases of differentiated human thyroid carcinoma with
adequate material available for research studies were
identified from the files of the Pathology Department of
Addenbrooke's Hospital. All specimens have been fixed in
10% formalin and routinely processed for paraffin wax
embedding. Five micron sections were cut and mounted on
3-aminopropylethoxysilane (APES)-coated slides and dried
overnight at room temperature. Serial sections were used for
immunohistochemical staining and ISH. The results were
scored on a semiquantitative basis by agreement between the
observers on a scale ranging from '-', undetectable, to
I + + +', uniform, very strong positivity. The distribution of
staining in the tumours with both immunocytochemistry and
ISH was in general uniform, so that the scoring reflects
intensity rather than the proportion of positive cells.
Immunocytochemistry
Two monoclonal mouse antibodies (generously supplied by
Professor K Siddle, Department of Clinical Biochemistry,
University of Cambridge) were used to detect human IGF-1
receptor (IGFR). These antibodies have been fully charac-
terised; they recognise distinct epitopes and neither antibody
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shows significant cross-reactivity with either the insulin recep-
tor or IGF-binding proteins (Soos et al., 1992). A dilution
profile for histochemical studies was carried out on a known
positive tissue (urothelium). Thyroid sections were incubated
overnight at 4°C in antibody at a dilution of 1:500. A
standard indirect peroxidase technique was used to localise
bound antibody using 3,3'-diaminobenzidine (DAB) as the
reporter molecule. Negative controls included omission of
primary antibody and use of an irrelevant mouse antibody of
the same IgG subclass (anti-bromodeoxyuridine, Sigma,
Poole, Dorset, UK).
in situ hybridisation
Two 30 mer antisense cDNA oligonucleotide sequences com-
plementary to the regions coding for amino acids 1-9 and
72-81 of IGF-I mRNA were used to detect IGF-1 mRNA.
The first probe showed 100% homology to the human
sequence and 97% to mouse and the second 97% homology
to man and 100% to mouse. Both sequences are shared by
the transcripts lA-and iB, showing no significant homology
with IGF-2 mRNA or any other known sequence and have
been used with success for ISH studies in mouse thyroid
(Thomas et al., 1994). The probes were labelled both 5' and
3' with digoxigenin (R&D Systems, Abingdon, UK). The
expression of K and A light chain mRNA was also studied by
ISH, using previously characterised cocktails of probes
(29 mer and 30 mer), labelled 5' and 3' with digoxigenin
(R&D Systems) at a concentration of 0.05 ng lil'.
The ISH technique used has been described in detail
elsewhere (Thomas et al., 1993). Briefly, sections were
digested in 1 lag ml-' proteinase K for 30 min at 37°C, prein-
cubated in hybridisation buffer for 1 h at 37°C and hyb-
ridised overnight in 45;l of the same buffer containing
0.5 ngfL of each IGF-1 probe. After washing in graded
concentrations of SSC to remove unbound probe, bound
probe was detected by alkaline phosphatase-linked anti-
digoxigenin antibody (1:500) and standard histochemistry
using nitroblue tetrazolium (NBT) as the reporter molecule.
Control sections were hybridised in the absence of labelled
probe or with the same concentration of a 5' 3' double-
labelled irrelevant probe, with similar length and GC content
to the test probe (EBER 1 mRNA; Khan et al., 1992). As a
measure of reproducibility of the technique sections of
known positive control tissues for IGF-l mRNA (mouse
thyroid and parathyroid) and EBER 1 mRNA (infectious
mononucleosis lymph node) were included each time the
technique was carried out.
Results
Five carcinomas showed the morphological features of fol-
licular carcinomas (Figure la). Four were trabecular or fol-
licular in structure, one of the four was widely invasive. One
tumour showed a solid, poorly differentiated pattern of
growth. Immunohistochemistry and ISH was positive for
thyroglobulin and negative for calcitonin in all tumours.
The 25 remaining tumours showed the morphological
features of papillary carcinoma. Sixteen showed typical
features, six were follicular variants, two showed mainly
oxyphil differentiation and one was classified as a diffuse
sclerosing variant. Five of the tumours with predominantly
papillary architecture showed widespread heavy lymphocytic
infiltrate within the fibroblastic core of papillae (Figure 2a).
The infiltrate appeared to be non-destructive and consisted
mainly of plasma cells. The remaining tumours showed little
or no lymphoid infiltrate.
In situ hybridisation
Sections from all tumours studied were uniformly positive on
hybridisation with the oligo(dT) probe and negative on hyb-
ridisation with EBER 1 mRNA probe. Both IGF-I probes
showed a similar staining pattern.
Normal thyroid follicular epithelium removed with the
tumours showed considerable intercellular heterogeneity for
IGF-I mRNA positivity by ISH. Positive follicular cells were
usually restricted to smaller, more active follicles lined by tall
columnar epithelium. Normal stroma contained no demons-
trable IGF-1 mRNA. The semiquantitative results for both
the normal and the neoplastic thyroid are shown in Table
I.
Four of the five cases of follicular carcinoma showed a
consistent, uniform and high IGF-I mRNA expression
throughout the tumour follicular cells, compared with a
much lower and heterogeneous hybridisation signal in the
follicular cells of the surrounding normal tissue (Figure lb).
A serial section hybridised with a probe to EBER 1 mRNA
was negative (Figure lc). The single case with a relatively
weaker expression was a widely invasive carcinoma, which
showed only scattered, isolated, strongly positive cells. These
cells, when reviewed on the haemaloxylin and eosin-stained
section were compatible with apoptotic cells. Tumour
stromal cells were negative.
Twenty of the 25 papillary carcinomas studied lacked any
demonstrable IGF-1 mRNA in the stroma. Of these 20, five
showed weak and 15 moderate positivity in the follicular
epithelium for IGF-I mRNA by ISH. There was no correla-
tion between morphology and the level of IGF-I mRNA
staining. Moderate positivity was observed in scattered lym-
phoid cells in areas of thyroiditis in the surrounding normal
tissue. This was confined to only a small proportion of
lymphoid cells within areas of thyroiditis. The remaining five
papillary carcinomas showed a heavy stromal lymphoplas-
macytic infiltrate which was strongly positive for IGF-I
mRNA. The positivity was confined to cells identified as
plasma cells by their morphology and by their content of
light chain mRNAs in serial sections. The plasma cell mRNA
positivity for IGF-I was uniformly strong, in contrast to that
seen in areas of thyroiditis (Figure 2b). The overlying fol-
licular epithelium showed only weak to moderate staining.
Further studies using digoxigenin-labelled oligoprobes for K
and A light chain mRNA revealed that the lymphoplas-
macytic infiltrate was polyclonal.
Immunocytochemistry
No significant staining was observed when slides were
incubated without primary antibody or with a control
antibody. Both IGF-I receptor antibodies used gave similar
results.
Immunohistochemistry for IGF-1 receptor gave uniformly
weak to negative results in both normal follicular epithelium
and stroma. In all cases of follicular carcinoma, IGF-1 recep-
tor immunohistochemistry showed a moderate and diffuse
positivity in tumour cells, with a mainly cytoplasmic distribu-
tion. Surrounding tissue stromal cells were mostly free of
immunostaining. The semiquantitative results for both the
normal and the neoplastic thyroid are shown in Table I.
Follicular epithelial cells in the majority (12/20) of the
papillary carcinomas lacking a lymphocytic infiltrate were
weakly positive on immunocytochemistry for IGF-I receptor.
The remainder (8/20) were moderately positive. There was no
demonstrable immunopositivity for IGF-1 receptor in
tumour stroma. In contrast, the follicular epithelium ofpapil-
lary carcinomas which contained a heavy lymphoplasmacytic
infiltrate within the fibroblastic core were uniformly strongly
positive for IGF-1 receptor (Figure 2c).
Discussion
We have used ISH to localise IGF-l mRNA and
immunocytochemistry to localise IGF-l receptor peptide in
differentiated thyroid carcinomas. We chose to use an app-
roach using ISH with oligonucleotide probes for localisation
of IGF-I as doubts have previously been raised about the
specificity of a number of IGF-1 antibodies because of cross-
reactivity with IGF-2 (Ollis et al., 1989), and because ISHInterdependence of epithelium and stroma in PTC
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Table I Semiquantitative analysis of the expression of IGF-l mRNA and IGF-l receptor peptide in
normal and neoplastic thyroid
IGF-J mRNA IGF-I receptor peptide
Epithelium Stroma Epithelium Stroma
Normal thyroid (n = 7) +/- - +/- -
Follicular carcinoma (n = 4) + + + - + -
Follicular carcinoma (n = 1) - - + -
Papillary carcinoma (n = 20) +/+ + - + -
Papillary carcinoma with lymphoid infiltrate (n = 5) + + + + + ++ -
a
b b
C C
Figure 1 Follicular carcinoma. (a) Follicular carcinoma of
trabecular morphology; stained with haematoxylin and eosin. (b)
All tumour follicular epithelial cells show moderately strong
positivity for IGF-l mRNA on hybridisation with IGF-I probe.
No counterstain has been used. (c) Semiserial section to b, hyb-
ridised with a probe to EBER 1 mRNA as a control. The
refractile connective tissue in the tumour stroma can be seen as a
faint network, but the section shows a complete lack of back-
ground staining. The inset shows the same probe hybridised
under the same conditions to a section of lymph node from a
case ofinfectious mononucleosis, showing strong positive staining
in the nuclei of the infected cells. The scale bars represent
50jLm.
Figure 2 Papillary carcinoma with lymphoid infiltrate. (a)
Tumour epithelial cells lining papillary structures. A heavy lym-
phoplasmacytic infiltrate is observed within the fibroblastic core
of the papillae. There is little evidence of epithelial destruction.
Stained with haematoxylin and eosin. The scale bar represents
501&m. (b) The lymphoplasmacytic infiltrate is strongly positive
for IGF-I mRNA on in situ hybridisation, whereas the tumour
epithelial cells are weakly positive. No counterstain has been
used. (c) Serial section to b, showing strong positivity for IGF-1
receptor peptide in tumour epithelial cells, with weak positivity in
the lymphoid infiltrate. Weak haematoxylin counterstain has been
used. The scale bars represent 50Im.
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gives more direct information on the cellular site of produc-
tion.
In the normal thyroid there is a heterogeneous distribution
of IGF-1 mRNA in follicular cells, with virtually no demons-
trable stromal positivity. These findings are similar to those
we have already observed in the adult mouse thyroid
(Thomas et al., 1994). There is also a very low expression of
the IGF-I receptor in normal follicular epithelium. In con-
trast, follicular epithelium in four of the five follicular car-
cinomas showed a uniformly high level of IGF-1 mRNA
expression, and weak positivity for the receptor peptide on
immunohistochemistry. This adds support to the hypothesis
that IGF-I is an important growth factor for thyroid fol-
licular cells and that autocrine secretion may be implicated in
thyroid follicular carcinogenesis (Williams et al., 1989). The
weak positivity observed on immunocytochemistry may be
due to down-regulation of the receptor as has been shown to
occur in cell culture when IGF-l peptide is present in the
culture medium (Werther et al., 1989).
In the majority of papillary carcinomas, there is weak to
moderate positivity for IGF-I mRNA in the epithelial cells,
and a low level of IGF-1 receptor peptide by
immunocytochemistry. Interestingly, a subset of papillary
carcinomas which have a marked lymphoplasmacytic
infiltrate showed a uniformly strong positivity for IGF-1
receptor peptide in the tumour cells on immunocytochemis-
try. The low level of IGF-1 mRNA demonstrated by ISH in
the epithelial cells did not significantly differ from that
observed in the papillary tumours lacking infiltrate. However,
the polyclonal lymphoplasmacytic infiltrate was strongly
positive for IGF-l mRNA. While an increased content of
IGF-1 mRNA does not prove that increased translation is
taking place, particularly as this is in part regulated by
post-transcriptional mechanisms (Hepler et al., 1990). These
results suggest that IGF-l produced by the stromal plasma
cell infiltrate may stimulate the growth of the overlying fol-
licular epithelium via the IGF-1 receptor present in increased
amounts on the epithelial cells.
These studies show that the follicular cell is the main
source of intrathyroid IGF-1 in both normal human thyroid
and follicular carcinoma, and provide evidence that epithelial
cells in papillary tumours produce this factor to a lesser
extent than the cells of follicular tumours. This suggests that
different growth factor pathways may be operative in papil-
lary thyroid carcinoma compared with follicular carcinoma;
an observation in keeping with the differential oncogene
expression (Bongarzone et al., 1989; Lemoine et al., 1989). It
has been suggested that epidermal growth factor (EGF)
receptor and transforming growth factor alpha TGF-o may
be involved in an autocrine loop in papillary carcinoma
(Haugen et al., 1992), but it is not clear whether this
mechanism is specific to papillary carcinoma. It has been
suggested previously that the subset of papillary tumours
which harbour a non-destructive lymphoplasmacytic infiltrate
may be a distinct entity with a different aetiology (Harach et
al., 1985). Our finding of high levels of IGF-1 mRNA in the
plasma cells in association with increased IGF-1 receptor
peptide in the tumour cells demonstrable by immunocyto-
chemistry are of particular interest. IGF-1 binding proteins,
are important regulators of IGF-I activity (Rechler and Niss-
ley, 1990). A recent study in the rat has shown that three
binding proteins are present, and that their individual levels
vary during hyperplasia and involution (Phillips et al., 1994).
It is clear therefore that changes in binding protein content
of the thyroid may have a considerable effect on the ability
of newly produced IGF-l to influence epithelial growth. We
have not carried out studies of the level of different binding
proteins in these tumours, nor have we carried out any
biological studies on the relationship between the tumour
cells and the stroma as all the material available to us is
fixed. However, we suggest that the most likely interpretation
of the observations is that there is a symbiotic relationship
between the tumour and the stromal infiltrate, with the
tumour cells producing an antigen which stimulates the lym-
phoid infiltrate, and the lymphoid cells producing IGF-1
which stimulates the growth of the tumour epithelial cells.
IGF-I is a known growth factor for thyroid follicular cell
lines derived from papillary carcinomas. Some papillary car-
cinoma cell lines have been shown to express IGF-1 receptor
and to proliferate in response to the supply of exogenous
IGF-l in the medium. A small amount of IGF-1 mRNA was
also detected using reverse transcriptase-polymerase chain
reaction (RT-PCR) in one cell line. (Onoda et al., 1992).
Although IGF-I has been identified as an important growth
factor for thyroid cells, it is clear that the regulation of
IGF-l is complex, and may be modulated not only by its
binding proteins, but also by other factors. In addition,
lymphoid cells are known to produce a variety of growth
factors including interleukins which can stimulate epithelial
cell growth.
Lymphoid infiltration occurs in a variety of tumours and is
usually interpreted as a cytotoxic immune response to a
tumour antigen. In some tumours the presence of a lymphoid
infiltrate may be a good prognostic indicator, for example in
colonic carcinoma (Jass et al., 1986) and nodular malignant
melanoma (Cook, 1994). In the particular subgroup of
thyroid papillary carcinomas we have studied, the lymphoid
infiltrate is mostly composed ofplasma cells, and confined to
the stroma, with virtually no evidence of lymphocytes cross-
ing the basement membrane or destruction of tumour cells.
The possibility that lymphoid stromal cells may be producing
growth factors which stimulate the growth of the epithelial
cells is clearly worth considering in any tumour with a diffuse
lymphoid infiltrate. In the thyroid of course, normal fol-
licular cells are stimulated to hyperfunction and growth by
antibodies in Graves' disease. In the salivary gland the so
called adenolymphoma or Warthin's tumour is an obvious
candidate for dependence of the tumour epithelium on a
factor produced by the lymphoid stroma. One important
tumour where there may be a link is nasopharyngeal car-
cinoma. Here the admixture is more intimate than in the
tumours we have studied.
The use of ISH to localise cells containing growth factor
mRNAs provides valuable information on the presumed site
of production. The parallel demonstration of cell content of
receptor by immunohistochemistry suggests that the cell con-
cerned may be able to respond to the appropriate signal.
Together they can be used to propose a hypothesis of autoc-
rine or paracrine growth control, and to point the way to
appropriate in vitro studies. It is important to establish extra
cellular mechanisms of growth control, not only to increase
our knowledge of the way tumour growth is mediated but
also because of the possibility of therapy directed to the
infiltrate rather than the tumour cells.
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